Bruton Agammaglobulinemia tyrosine Kinase (BTK) (N-Term) Peptid
BTK
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle BTK Produkte
- BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))
- Protein Region
- N-Term
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- LTVHKLSYYE YDFERGRRGS KKGSIDVEKI TCVETVVPEK NPPPERQIPR
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-BTK Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))
- Hintergrund
-
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms.
Alias Symbols: AT, ATK, BPK, XLA, IMD1, AGMX1, PSCTK1
Protein Size: 483 - Gen-ID
- 695
- NCBI Accession
- NM_000061, NP_000052
- UniProt
- Q5JY90
-
Sie sind hier:
